Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 292Urinary Bladder Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 24Carcinoma, Transitional Cell 23Neoplasms 21Breast Neoplasms 20Lung Neoplasms 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Non-Muscle Invasive Bladder Neoplasms 10Melanoma 9Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Prostatic Neoplasms, Castration-Resistant 7Head and Neck Neoplasms 7Esthesioneuroblastoma, Olfactory 7Esophageal Neoplasms 7Colorectal Neoplasms 7Urethral Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Prostate Cancer Metastatic 5Pancreatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Kidney Neoplasms 5Adenocarcinoma 5Sarcoma 4

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Docetaxel × Genitourinary × Clear all
NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

BioNTech SE

Phase 3 Recruiting
736 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02044354 2026-04-01

CABA-DOC

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
195 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Rigshospitalet, Denmark

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05762536 2024-06-27

DAROTAXEL

Erasmus Medical Center

Phase 2 Recruiting
245 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04586543 2020-10-14

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

University of Pecs

Phase 2 Unknown
110 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡